---
title: Bone Metabolism Drugs
type: content
phase: 1
status: complete
priority: high
tags: [osteoporosis, bisphosphonates, denosumab, teriparatide, calcium, vitamin-D, bone-metabolism]
created: 2025-11-08
last_modified: 2025-11-08
---

# Bone Metabolism Drugs

## Introduction

Bone metabolism disorders, particularly osteoporosis, are common conditions affecting millions worldwide. Understanding the pharmacologic agents that modulate bone formation and resorption is essential for preventing fractures and managing bone health.

## Bone Physiology

### Bone Remodeling

**Continuous Process**:
1. **Resorption**: **Osteoclasts** break down old bone (2-4 weeks)
2. **Formation**: **Osteoblasts** build new bone (4-6 months)
3. **Balance**: Resorption = Formation (adult bone mass stable)

**Coupled Process**:
- Osteoclasts and osteoblasts communicate
- Normal: Tight coupling maintains bone mass

**Osteoporosis**: ↑Resorption > ↑Formation → net bone loss

### Key Factors in Bone Metabolism

**Calcium and Phosphate**:
- Major mineral components (hydroxyapatite crystals)
- Blood levels tightly regulated

**Parathyroid Hormone (PTH)**:
- **↑Blood Ca2+** (when hypocalcemic):
  - ↑Bone resorption (osteoclasts)
  - ↑Renal Ca2+ reabsorption
  - ↑Renal 1,25(OH)2D production → ↑intestinal Ca2+ absorption
- **Net effect**: ↑Blood Ca2+, ↑bone resorption

**Vitamin D** (Calcitriol - 1,25(OH)2D):
- **↑Intestinal Ca2+ and PO4 absorption** (primary action)
- ↑Bone mineralization
- Permissive for PTH actions

**Calcitonin**:
- **↓Bone resorption** (osteoclasts)
- Minimal role in humans (unlike salmon calcitonin - drug)

**Estrogen**:
- **↓Bone resorption** (inhibits osteoclasts)
- Loss at menopause → accelerated bone loss

**RANK/RANKL/OPG System**:
- **RANKL**: Osteoblast-produced, activates osteoclasts
- **RANK**: Receptor on osteoclasts
- **OPG** (osteoprotegerin): Decoy receptor, binds RANKL → ↓osteoclast activation

---

## Classification of Bone Drugs

### Antiresorptive Agents (↓Osteoclast Activity)
1. **Bisphosphonates**: Alendronate, risedronate, ibandronate, zoledronic acid
2. **RANKL Inhibitor**: Denosumab
3. **Selective Estrogen Receptor Modulators (SERMs)**: Raloxifene
4. **Calcitonin**: Salmon calcitonin

### Anabolic Agents (↑Osteoblast Activity)
1. **PTH Analogs**: Teriparatide, abaloparatide
2. **Sclerostin Inhibitor**: Romosozumab

### Essential Nutrients
1. **Calcium**
2. **Vitamin D**

---

## Bisphosphonates

### Mechanism of Action

**Structure**: Pyrophosphate analogs (P-C-P bond - resistant to hydrolysis)

**Mechanism**:
1. **Bind to hydroxyapatite** (bone mineral) - high affinity
2. **Ingested by osteoclasts** during bone resorption
3. **↓Osteoclast activity**:
   - **Nitrogen-containing** (alendronate, risedronate, ibandronate, zoledronic acid):
     - Inhibit farnesyl pyrophosphate synthase (mevalonate pathway)
     - ↓Protein prenylation → ↓osteoclast function
   - **Non-nitrogen** (etidronate, clodronate - rarely used):
     - Toxic ATP analogs → apoptosis
4. **↑Osteoclast apoptosis**

**Net Effect**: **↓Bone resorption** → preserve or ↑bone mass

### Individual Agents

#### Alendronate (Fosamax)

**Formulations**: Oral (daily, weekly)

**Pharmacokinetics**:
- **Poor oral absorption** (<1%):
  - **Take on empty stomach** with water
  - **Remain upright 30 minutes** (prevent esophagitis)
  - **No food/drink 30 minutes** (↓absorption)
- **Long bone half-life** (years - bound to bone)
- **Renal excretion** (unchanged)

**Clinical Uses**:
1. **Osteoporosis** (treatment and prevention) - **first-line**
2. **Glucocorticoid-induced osteoporosis**
3. **Paget's disease**

**Dosing**:
- **Osteoporosis treatment**: 70 mg once weekly (or 10 mg daily)
- **Osteoporosis prevention**: 35 mg once weekly (or 5 mg daily)
- **Weekly preferred** (compliance)

**Efficacy**:
- **↓Vertebral fractures** 50%
- **↓Hip fractures** 50%
- **↑BMD** 5-10% (spine/hip)

**Adverse Effects**:

**GI** (Most Common):
- **Esophagitis, esophageal ulcers** (5-10%):
  - **Prevention**: Take with full glass of water, remain upright 30 min
  - **Stop if dysphagia, odynophagia**
- **GERD, dyspepsia**
- **Contraindicated**: Esophageal stricture, achalasia, unable to stand/sit upright

**Musculoskeletal**:
- **Musculoskeletal pain** (rare, can be severe)

**Atypical Femoral Fractures** (Rare, <0.01%):
- Subtrochanteric or diaphyseal fractures
- **Risk**: Long-term use (>5 years)
- Prodromal thigh pain
- **Drug holiday** considered after 5-10 years

**Osteonecrosis of Jaw (ONJ)** (Very Rare, <0.001%):
- **Risk factors**: Dental procedures, high IV doses (cancer), poor oral hygiene
- **Prevention**: Dental exam before starting, good oral hygiene
- Much more common with high-dose IV (cancer patients)

**Hypocalcemia**:
- Transient ↓Ca2+ (mild)
- Ensure adequate Ca2+/vitamin D intake

**Renal**:
- Contraindicated if CrCl <35 mL/min

**Clinical Pearls**:
- **Weekly dosing** preferred (compliance, less GI effects)
- **Administration**: Empty stomach, upright 30 min, water only
- **Drug holiday** after 5-10 years (consider risk/benefit)
- **Most commonly prescribed bisphosphonate**

#### Risedronate (Actonel)

**Similar to alendronate**

**Formulations**: Oral (daily, weekly, monthly)

**Dosing**:
- **Osteoporosis treatment**: 35 mg once weekly (or 5 mg daily, or 150 mg monthly)
- **Glucocorticoid-induced**: 5 mg daily

**Advantages**:
- **Possibly less GI toxicity** than alendronate (controversial)
- Monthly option available

**Administration**: Similar to alendronate (empty stomach, upright 30 min)

#### Ibandronate (Boniva)

**Formulations**: Oral (monthly), **IV (quarterly)**

**Dosing**:
- **Oral**: 150 mg once monthly
- **IV**: 3 mg q3 months

**Advantages**:
- **IV formulation** (if cannot tolerate oral)
- **Less frequent** (monthly oral, quarterly IV)

**Note**: **Data for hip fracture reduction less robust** than alendronate/risedronate

#### Zoledronic Acid (Reclast)

**Formulation**: **IV only** (annual infusion)

**Dosing**:
- **Osteoporosis treatment**: 5 mg IV once yearly
- **Osteoporosis prevention**: 5 mg IV every 2 years
- **Paget's disease**: 5 mg IV × 1

**Administration**:
- IV infusion over 15-30 minutes
- Ensure adequate hydration, Ca2+/vitamin D

**Clinical Uses**:
1. **Osteoporosis** (treatment/prevention) - **annual dosing**
2. **Glucocorticoid-induced osteoporosis**
3. **Paget's disease**
4. **Hypercalcemia of malignancy** (Zometa - higher dose)
5. **Bone metastases** (cancer - higher dose)

**Advantages**:
- **Annual dosing** (best compliance)
- **Most potent** bisphosphonate
- **No GI side effects** (IV)
- **Proven hip fracture reduction**

**Adverse Effects**:

**Acute-Phase Reaction** (30-40%, first infusion):
- Fever, myalgias, arthralgias, headache
- Usually 24-72 hours post-infusion
- **Less common with subsequent infusions**
- **Prevention**: Acetaminophen pre/post-infusion

**Hypocalcemia**:
- More pronounced than oral bisphosphonates
- **Ensure adequate Ca2+/vitamin D** before and after

**Renal**:
- **Contraindicated if CrCl <35 mL/min**
- Check renal function before each dose

**Atrial Fibrillation**:
- Possible ↑risk (controversial, HORIZON trial)

**Atypical fractures, ONJ**: Same as oral bisphosphonates (rare)

**Clinical Pearls**:
- **Best compliance** (annual infusion)
- **Acute-phase reaction common** (first dose) - warn patient
- **Pretreat with acetaminophen**
- **Good for patients with GI intolerance to oral bisphosphonates**

### General Bisphosphonate Considerations

**Duration of Therapy**:
- **Drug holiday** considered after **5 years** (oral) or **3 years** (IV):
  - Low fracture risk: Consider stopping
  - High fracture risk: Continue (previous fracture, very low BMD, glucocorticoids)
- **Rationale**: Long bone half-life (years), atypical fracture risk

**Monitoring**:
- **BMD** (DXA scan): Every 1-2 years initially, then less frequently
- **Renal function** annually
- **Calcium, vitamin D levels**

**Contraindications**:
- **CrCl <35 mL/min** (renal excretion)
- **Hypocalcemia** (correct first)
- **Esophageal disorders** (oral - stricture, achalasia, unable to stand)
- Pregnancy

---

## Denosumab (Prolia)

### Mechanism

**Target**: **RANKL** (receptor activator of NF-κB ligand)

**Mechanism**:
- **Monoclonal antibody** against RANKL
- **Blocks RANKL-RANK interaction**
- **↓Osteoclast formation, activity, survival**
- Mimics endogenous OPG (osteoprotegerin)

**Effect**: **Powerful antiresorptive** (more than bisphosphonates)

### Pharmacokinetics

- **SC injection** (every 6 months)
- **Long half-life** (~26 days)
- **Not renally excreted** (protein, catabolized)

### Clinical Uses

1. **Osteoporosis** (postmenopausal women, men) - **alternative to bisphosphonates**
2. **Bone loss** during androgen deprivation (prostate cancer)
3. **Bone loss** during aromatase inhibitor therapy (breast cancer)
4. **Giant cell tumor of bone** (Xgeva - higher dose)
5. **Bone metastases** (Xgeva - higher dose, monthly)

### Dosing

- **Prolia** (osteoporosis): 60 mg SC q6 months
- **Xgeva** (cancer): 120 mg SC monthly

### Advantages

- **SC administration** (no GI effects)
- **Every 6 months** (good compliance)
- **Safe in renal impairment** (no renal excretion)
- **More potent** than bisphosphonates (↑BMD)
- **Rapid offset** (wears off after 6 months - unlike bisphosphonates)

### Adverse Effects

**Hypocalcemia**:
- More common than bisphosphonates
- **Monitor Ca2+**, especially if CrCl <30
- **Ensure adequate Ca2+/vitamin D** (1000 mg Ca2+, 400 IU D)

**Infections**:
- ↑Cellulitis, eczema (immunosuppression)
- Monitor for signs of infection

**Atypical Femoral Fractures**:
- Similar risk to bisphosphonates (rare)

**Osteonecrosis of Jaw (ONJ)**:
- Similar to bisphosphonates (rare)

**Rebound Bone Loss** (Important):
- **Rapid ↑bone resorption** when stopped (unlike bisphosphonates)
- **↑Vertebral fracture risk** if discontinue without follow-on therapy
- **Must transition** to bisphosphonate if stopping

**Clinical Pearls**:
- **Good alternative** if cannot tolerate oral bisphosphonates
- **Safe in renal impairment** (unlike bisphosphonates)
- **Monitor Ca2+** (hypocalcemia risk)
- **Never stop abruptly** (rebound bone loss) - transition to bisphosphonate

---

## Selective Estrogen Receptor Modulators (SERMs)

### Raloxifene (Evista)

**Mechanism**:
- **Selective estrogen receptor modulator**
- **Agonist**: Bone, lipids
- **Antagonist**: Breast, uterus

**Pharmacokinetics**:
- Oral, once daily
- Hepatic metabolism

**Clinical Uses**:
1. **Osteoporosis prevention/treatment** (postmenopausal women)
2. **Breast cancer risk reduction** (high-risk women)

**Dosing**: 60 mg once daily

**Efficacy**:
- **↓Vertebral fractures** 40-50%
- **NO hip fracture reduction** (unlike bisphosphonates)
- **↓Breast cancer risk** 70% (invasive, ER-positive)

**Advantages**:
- **↓Breast cancer risk** (unique benefit)
- ↑HDL, ↓LDL
- No endometrial stimulation (vs. estrogen)

**Adverse Effects**:

**Venous Thromboembolism (VTE)** (↑3x risk):
- Deep vein thrombosis, pulmonary embolism
- **Contraindicated**: History of VTE
- **Discontinue** before prolonged immobilization (surgery)

**Hot Flashes** (Worsens):
- Estrogen antagonist effect (vasomotor)
- Limits use in women with hot flashes

**Leg Cramps**:
- Common

**Stroke**:
- Possible ↑risk (RUTH trial - high-risk women)

**Contraindications**:
- **History of VTE** (DVT, PE)
- **Active or high VTE risk**
- Pregnancy, women of childbearing potential

**Clinical Pearl**: **Good for women** who want breast cancer risk reduction + osteoporosis prevention (but not hip fracture reduction)

---

## Calcitonin

### Salmon Calcitonin (Miacalcin)

**Mechanism**:
- **↓Osteoclast activity** (calcitonin receptor)
- **Analgesic effect** (acute fractures - unclear mechanism)

**Formulations**: Nasal spray (discontinued in some countries), injectable

**Clinical Uses**:
1. **Paget's disease** (historical)
2. **Acute pain** from vertebral compression fractures
3. **Hypercalcemia** (rarely used)
4. **Osteoporosis** (second/third-line - limited efficacy)

**Dosing**:
- **Nasal**: 200 IU/day (alternating nostrils)
- **Injectable**: 100 IU SC/IM daily

**Efficacy**:
- **↓Vertebral fractures** (modest, controversial)
- **NO hip fracture reduction**
- **Analgesic** for acute fracture pain

**Adverse Effects**:
- **Nasal irritation** (rhinitis)
- **Nausea** (injectable)
- **Flushing**
- **Cancer risk** (controversial - removed from European market)

**Clinical Pearl**: **Mainly used for acute fracture pain** (analgesic effect) - not first-line osteoporosis

---

## Anabolic Agents

### Teriparatide (Forteo)

**Structure**: **Recombinant human PTH (1-34)** (N-terminal fragment)

**Mechanism**:
- **Intermittent (pulsatile) PTH** → **↑bone formation** (anabolic)
- **Continuous PTH** → ↑bone resorption (catabolic - hyperparathyroidism)
- Pulsatile dosing: **↑Osteoblast** activity > ↑osteoclast

**Pharmacokinetics**:
- **SC injection** daily
- Short half-life (1 hour)

**Clinical Uses**:
1. **Severe osteoporosis** (high fracture risk):
   - Previous fracture
   - Very low BMD (T-score < -3.5)
   - Multiple risk factors
   - Failed bisphosphonates
2. **Glucocorticoid-induced osteoporosis** (high fracture risk)

**Dosing**: 20 mcg SC daily (maximum **2 years lifetime**)

**Efficacy**:
- **↓Vertebral fractures** 65%
- **↓Non-vertebral fractures** 53%
- **↑BMD** significantly (spine 10%, hip 3%)
- **Most effective** osteoporosis drug (for vertebral fractures)

**Advantages**:
- **Only anabolic agent** (↑bone formation)
- **Most effective** for vertebral fracture reduction
- Can **rebuild bone** (vs. just slow loss)

**Adverse Effects**:

**Hypercalcemia**:
- Transient ↑Ca2+ (PTH effect)
- Usually mild
- Monitor Ca2+

**Orthostatic Hypotension**:
- First doses
- Inject while sitting/lying

**Leg Cramps**:
- Common

**Osteosarcoma** (Animal Studies):
- **Black Box Warning**: Osteosarcoma in rats (high doses, lifetime)
- **No human cases** reported
- **Contraindicated**: Paget's disease, bone metastases, skeletal radiation, pediatric (open epiphyses)

**Hypercalciuria**:
- ↑Urinary Ca2+ (kidney stones risk)

**Contraindications**:
- **Paget's disease**
- **Bone metastases, skeletal malignancies**
- **Prior skeletal radiation**
- **Hypercalcemia**
- **Pediatric** (open growth plates)

**Limitations**:
- **Maximum 2 years lifetime** (osteosarcoma risk, though theoretical)
- **Expensive** (>$1000/month)
- **Daily injections** (compliance)

**Follow-On Therapy**:
- **Must follow with antiresorptive** (bisphosphonate, denosumab)
- Bone loss occurs if stop without follow-on

**Clinical Pearls**:
- **Reserve for severe osteoporosis** (high fracture risk)
- **Most effective** for vertebral fractures
- **Limited to 2 years** lifetime use
- **Always follow with antiresorptive** (bisphosphonates)

### Abaloparatide (Tymlos)

**Similar to teriparatide**: PTH-related peptide analog

**Advantages**:
- Possibly less hypercalcemia than teriparatide
- Similar efficacy

**Dosing**: 80 mcg SC daily (maximum 2 years)

**Clinical Pearl**: **Alternative to teriparatide** (similar benefits/risks)

### Romosozumab (Evenity)

**Mechanism**:
- **Monoclonal antibody** against **sclerostin**
- Sclerostin inhibits osteoblasts
- **Dual effect**: ↑Bone formation + ↓bone resorption

**Dosing**: 210 mg SC monthly × 12 months

**Efficacy**:
- **↓Vertebral fractures** 73%
- **↓Hip fractures** 38%
- Rapid ↑BMD

**Adverse Effects**:
- **Cardiovascular events** (MI, stroke):
  - **Black Box Warning**
  - Avoid if MI/stroke within prior year
- Hypocalcemia
- ONJ, atypical fractures (rare)

**Contraindications**:
- **MI or stroke within past year**
- Hypocalcemia

**Clinical Pearl**: **Newest anabolic** - potent but cardiovascular concerns (reserve for high-risk patients without CV disease)

---

## Calcium and Vitamin D

### Calcium

**Dietary Sources**: Dairy, fortified foods, leafy greens

**Recommended Intake**:
- **Postmenopausal women**: 1200 mg/day
- **Men >70 years**: 1200 mg/day
- **Younger adults**: 1000 mg/day

**Supplements**:
- **Calcium carbonate** (40% elemental Ca2+):
  - Take with food (requires acid)
  - Inexpensive
- **Calcium citrate** (21% elemental Ca2+):
  - Take anytime (acid-independent)
  - Better absorbed in achlorhydria, PPI use
  - More expensive

**Dosing**:
- **500 mg elemental Ca2+ per dose** (maximum absorption)
- Divide doses if >1000 mg/day

**Adverse Effects**:
- **Constipation** (common)
- **Kidney stones** (if excessive, especially with low fluid)
- **Cardiovascular risk** (controversial - possibly ↑MI with high-dose supplements)

**Clinical Pearls**:
- **Dietary preferred** over supplements (if possible)
- **Calcium citrate better** in elderly (achlorhydria, PPI use)
- **Split doses** (max 500 mg per dose)
- **Separate from thyroid medication** by 4 hours

### Vitamin D

**Synthesis**: Skin (UV) → vitamin D3 → 25(OH)D (liver) → **1,25(OH)2D** (kidney - active)

**Functions**:
- **↑Intestinal Ca2+ absorption** (primary)
- Bone mineralization
- Muscle function, immune function

**Deficiency**:
- **Rickets** (children), **osteomalacia** (adults)
- Proximal myopathy

**Recommended Intake**:
- **600-800 IU/day** (general population)
- **Higher** if deficient (1000-2000 IU/day)

**Supplements**:
- **Vitamin D3** (cholecalciferol) - preferred (more potent, longer-lasting)
- **Vitamin D2** (ergocalciferol) - less potent

**Monitoring**:
- **25(OH)D levels** (storage form):
  - **Goal**: >30 ng/mL (>75 nmol/L)
  - **Deficiency**: <20 ng/mL
  - **Insufficiency**: 20-30 ng/mL

**Dosing**:
- **Maintenance**: 800-2000 IU/day
- **Deficiency**: 50,000 IU weekly × 8-12 weeks, then maintenance

**Toxicity** (Rare, >10,000 IU/day chronically):
- **Hypercalcemia**: Nausea, confusion, kidney stones, renal failure
- Wide therapeutic window (safe up to 4000 IU/day)

**Clinical Pearls**:
- **D3 preferred** over D2
- **Check 25(OH)D level** (not 1,25(OH)2D)
- **Safe and inexpensive** - supplement liberally
- **Essential adjunct** to osteoporosis therapy

---

## Treatment Approach to Osteoporosis

### Risk Assessment

**Indications for Treatment**:
1. **Prior osteoporotic fracture** (hip, vertebral)
2. **T-score ≤ -2.5** (spine, hip, femoral neck)
3. **T-score -1.0 to -2.5 + high FRAX risk**:
   - 10-year hip fracture risk ≥3%
   - 10-year major fracture risk ≥20%

### First-Line Therapy

**Postmenopausal Women, Men**:
- **Oral bisphosphonate** (alendronate, risedronate) - **first-line**
- OR **IV bisphosphonate** (zoledronic acid) - if GI intolerance
- OR **Denosumab** - if cannot tolerate bisphosphonates or renal impairment

**Plus**:
- **Calcium** 1200 mg/day (diet + supplement)
- **Vitamin D** 800-2000 IU/day

### High Fracture Risk

**Very High Risk** (prior fracture, very low BMD, multiple risk factors):
- **Teriparatide or romosozumab** (anabolic) × 1-2 years
- **Then** transition to bisphosphonate or denosumab

### Glucocorticoid-Induced Osteoporosis

**Prevention/Treatment**:
- **Bisphosphonate** (first-line)
- OR **Teriparatide** (if very high risk)
- Plus Ca2+/vitamin D

### Monitoring

- **BMD** (DXA scan): Every 1-2 years
- Assess fracture risk, compliance, adverse effects

---

## Clinical Pearls

1. **Bisphosphonates first-line** (oral or IV)
2. **Alendronate weekly dosing** most common (compliance)
3. **Zoledronic acid annual** best compliance (IV)
4. **Administration**: Oral bisphosphonates on empty stomach, upright 30 min
5. **Drug holiday** after 5 years (consider risk/benefit)
6. **Denosumab** good for renal impairment (no renal excretion)
7. **Never stop denosumab abruptly** (rebound bone loss) - transition to bisphosphonate
8. **Teriparatide** for severe osteoporosis (most effective vertebral fracture reduction), limit 2 years
9. **Always follow anabolic** with antiresorptive (bisphosphonates)
10. **Calcium 1200 mg + vitamin D 800 IU** daily - **essential adjuncts**
11. **Check vitamin D level** (goal >30 ng/mL)
12. **Atypical fractures, ONJ rare** but increase with long-term bisphosphonates (>5 years)

---

## Key Takeaways

1. **Bisphosphonates**: ↓Osteoclast activity, first-line osteoporosis treatment
2. **Alendronate**: Weekly oral, take on empty stomach upright 30 min, GI side effects
3. **Zoledronic acid**: Annual IV, best compliance, acute-phase reaction common
4. **Denosumab**: RANKL inhibitor, SC q6 months, safe in renal impairment, rebound bone loss if stop
5. **Teriparatide**: Anabolic (↑osteoblast), SC daily, maximum 2 years, severe osteoporosis
6. **Raloxifene**: SERM, ↓vertebral fractures (not hip), ↓breast cancer, ↑VTE risk
7. **Drug holiday**: Consider after 5 years bisphosphonates (atypical fracture risk)
8. **Calcium 1200 mg + vitamin D 800 IU**: Essential adjuncts to all osteoporosis therapy
9. **Treatment approach**: Bisphosphonates first-line, teriparatide if severe, always add Ca2+/D
10. **Monitoring**: BMD every 1-2 years, vitamin D level, assess fractures

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020
4. National Osteoporosis Foundation Guidelines
5. Black DM, et al. Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. N Engl J Med. 2010.
6. FDA Drug Safety Communications - Bisphosphonates
